Novo Nordisk presentation on the European Society of Nephrology held in Stockholm, Sweden on the twenty fourth. Reporter Nam Jeong-min The primary corridor of the European Society of Nephrology (ERA 2024) was held in Stockholm, Sweden on the twenty fourth. Attended by greater than 2,200 kidney illness consultants from all over the world and we ran out of time. That is to listen to the outcomes of a medical trial in continual kidney illness utilizing semaglutide, the identical ingredient in Wegobi, the weight problems therapy from Danish pharmaceutical firm Novo Nordisk. The outcome was optimistic. Medical outcomes displaying it reduces the danger of loss of life in sufferers with continual kidney illness by 20% have sparked reactions within the subject, calling it a “historic second.”
The headliner of this 12 months’s ERA 2024 was weight problems. At Europe’s largest educational kidney illness occasion, held from the twenty third to the twenty sixth, a joint analysis workforce from america, Australia and Europe unveiled knowledge from the Section 3 medical trial of FLOW utilizing semaglutide. It was designed to look at how the speed of illness development may very well be slowed by weekly administration of semaglutide, a glucagon-like peptide (GLP)-1 therapy, to sufferers with continual kidney illness.
Essentially the most incessantly heard phrase on the scene was: “It clearly confirmed superiority over counterfeit medicine.” 3,533 sufferers with continual kidney illness had been divided into two teams and obtained placebo medicine and semaglutide. Semaglutide diminished the mortality fee by 20%. The danger of worsening illness, similar to dialysis or kidney transplant surgical procedure on account of continual kidney failure, was diminished by 24%. There are 800 million folks affected by continual kidney illness worldwide. Professor Vlado Perkovic from the College of Sydney, Australia, who gave the presentation right now, mentioned: “We now have demonstrated the protection of semaglutide when administered to folks with kidney illness and diabetes, additional growing the longer term worth of the drug.” . Catherine Tuttle, professor on the College of Washington, additionally current on stage on the presentation, acknowledged: “Semaglutide will develop into a brand new pillar within the therapy of continual kidney illness” and underlined: “This drug saves the kidneys and the affected person’s life” .
The viewers clapped and cheered. A German medical skilled mentioned: “The medical outcomes are very shocking” and “It’s important to be current at this historic session.” The outcomes of the stream research had been additionally printed within the worldwide educational journal New England Journal of Medication (NEJM).
Stockholm = journalist Nam Jeong-min peux@hankyung.com
#Reduces #threat #loss of life #20.. #Weight problems #circumstances #exploded #historic #second
